Picture of Q Linea AB logo

QLINEA Q Linea AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-5.05%
3m-40.71%
6m-41.3%
1yr-68.63%
Volume Change (%)
10d/3m-83.9%
Price vs... (%)
52w High-79.95%
50d MA-6.43%
200d MA-36.17%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-113.85%
Return on Equity-130.02%
Operating Margin-5193.4%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Q Linea AB EPS forecast chart

Profile Summary

Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 27th, 2007
Public Since
December 7th, 2018
No. of Employees
127
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
117,166,372

QLINEA Share Price Performance

Upcoming Events for QLINEA

Q1 2024 Q linea AB Earnings Release

Q linea AB Annual Shareholders Meeting

Q linea AB Annual Shareholders Meeting

Q2 2024 Q linea AB Earnings Release

Half Year 2024 Q linea AB Earnings Release

Similar to QLINEA

Picture of Acarix AB logo

Acarix AB

se flag iconOMX Nordic Exchange Stockholm

Picture of ADDvise AB (publ) logo

ADDvise AB (publ)

se flag iconOMX Nordic Exchange Stockholm

Picture of ADDvise AB (publ) logo

ADDvise AB (publ)

se flag iconOMX Nordic Exchange Stockholm

Picture of Aegirbio AB logo

Aegirbio AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Arcoma AB logo

Arcoma AB

se flag iconOMX Nordic Exchange Stockholm

FAQ